FDA, COVID-19 and vaccine
Digest more
The House Judiciary Committee revealed Thursday that Pfizer’s former Global Head of Vaccines Research and Development, Dr. Philip Dormitzer, may have “conspired to withhold public
US regulators will no longer approve Covid booster shots for healthy adults and children without new studies, adding a costly requirement for drugmakers, though they will still be available for millions of high-risk Americans.
The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company executive to investigate an allegation that clinical testing related to the development of the company’s Covid-19 vaccine was purposefully delayed until after the 2020 presidential election.
Help Register Login Login Hi, %{firstName}% Hi, %{firstName}% Games Car rental The U.S. Food and Drug Administration (FDA) has officially approved a COVID-19 vaccine from Novavax for adults 65 and older and for individuals ages 12 to 64 who have an underlying health condition that puts them at higher risk for serious illness from a coronavirus infection.
A former Pfizer scientist said the timing of the 2020 vaccine results “wasn’t a coincidence,” according to allegations provided by a rival drugmaker.
Explore more
Novavax makes the nation’s only traditional protein-based coronavirus vaccine – and until now it had emergency authorization from FDA for use in anyone 12 and older. What's the change?
2d
Stocktwits on MSNNovavax Wins FDA Approval For COVID-19 Vaccine: Retail Calls For Buyback And Bigger MovesNovavax Inc. drew retail attention on Friday after receiving a Biologics License Application for its COVID-19 vaccine, Nuvaxovid, from the U.S. Food and Drug Administration. Novavax shares closed at $6.